Contact information
melanie.greenland@paediatrics.ox.ac.uk
https://orcid.org/0000-0001-9363-8844
Oxford Vaccine Group, CCVTM, Churchill Rd, Headington, Oxford, OX3 7LE
She/her
Research groups
Melanie Greenland
MSc BSc
Senior Medical Statistician
Melanie is a Medical Statistician at the Oxford Vaccine Group with experience of clinical trials in vaccinology, women's reproductive health, obstetrics and neonatal research. She also has experience in epidemiology in cardiovascular research using linked electronic health data and Biobank data. She holds a BSc in Mathematics and MSc in Biometry. She joined the team in 2020 and is currently involved in COVID, typhoid fever and pregnancy vaccine trials. Her current research interests include understanding the associations between reactogenicity following vaccination, immune responses and genetics.
Key publications
-
Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial.
Journal article
Liu X. et al, (2021), Lancet, 398, 856 - 869
-
Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data.
Journal article
Shaw RH. et al, (2021), Lancet, 397, 2043 - 2046
-
Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial.
Journal article
Stuart ASV. et al, (2022), Lancet, 399, 36 - 49
Recent publications
-
Planned Delivery for Pre-eclampsia between 34 and 37 weeks of gestation: the PHOENIX randomised controlled trial.
Journal article
HARDY P. et al, (2022), Health Technology Assessment
-
Phase 1/2a Safety and Immunogenicity of an Adenovirus 26 Vector RSV Vaccine Encoding Prefusion F in Adults 18-50 Years and RSV Seropositive Children 12-24 Months.
Journal article
Stuart A. et al, (2022), J Infect Dis